Global Blood Therapeutics Inc (NASDAQ:GBT)

55.58
Delayed Data
As of Oct 21
 -3.06 / -5.22%
Today’s Change
39.95
Today|||52-Week Range
87.54
-30.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.9B

Company Description

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Contact Information

Global Blood Therapeutics, Inc.
181 Oyster Point Boulevard
South San Francisco California 94080
P:(650) 741-7700
Investor Relations:
(650) 741-7730

Employees

Shareholders

Mutual fund holders57.89%
Other institutional49.25%
Individual stakeholders15.31%

Top Executives

Ted W. LovePresident, Chief Executive Officer & Director
Nazila HabibizadSenior Vice President-Operations
Jeffrey S. FarrowChief Financial & Accounting Officer
Brian CathersChief Scientific Officer
Jung E. ChoiChief Business & Strategy Officer